3,5-dichloro-4-(4-hydroxy-3-isopropylphenoxy)phenylformylimino diacetic acid | 280779-28-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,5-dichloro-4-(4-hydroxy-3-isopropylphenoxy)phenylformylimino diacetic acid
• 英文别名: 2-[Carboxymethyl-[3,5-dichloro-4-(4-hydroxy-3-propan-2-ylphenoxy)benzoyl]amino]acetic acid
• CAS: 280779-28-4
• 化学式: C₂₀H₁₉Cl₂NO₇
• 分子量: 456.279
• InChiKey: YIRYCEMCBKAYQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  124
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  diethyl 2,2'-((3,5-dichloro-4-(3-isopropyl-4-methoxyphenoxy)benzoyl)azanediyl)diacetate 在 三溴化硼 、 lithium hydroxide 、 水 作用下， 以 二氯甲烷 、 四氢呋喃 为溶剂， 反应 3.0h， 以38%的产率得到3,5-dichloro-4-(4-hydroxy-3-isopropylphenoxy)phenylformylimino diacetic acid
  参考文献：
  名称：

  Novel thyroid receptor ligands and method II

  摘要：

  提供了新的甲状腺受体配体，其具有以下通式（I）：其中：n是从0到4的整数；R1是卤素、三氟甲基或1至6个碳原子的烷基或3至7个碳原子的环烷基；R2和R3相同或不同，是氢、卤素、1至4个碳原子的烷基或3至5个碳原子的环烷基，其中至少有一个是氢之外的其他基团；R4是其羧酸；或当n等于或大于1时，R4可以是杂环芳基团，可能被取代或未取代，或胺（NR′R″）。R5是氢或酰基（如乙酰基或苯甲酰基）或其他能够生物转化以生成游离酚结构（其中R5-H）的基团。此外，提供了一种方法，用于预防、抑制或治疗与代谢功能障碍相关或依赖于T3调节基因表达的疾病，其中上述描述的化合物以治疗有效剂量给予。与代谢功能障碍相关或依赖于T3调节基因表达的疾病的例子包括肥胖症、高胆固醇血症、动脉粥样硬化、心律失常、抑郁症、骨质疏松症、甲状腺功能减退症、甲状腺肿、甲状腺癌以及青光眼、充血性心力衰竭和皮肤疾病。

  公开号：

  US20050282872A1

文献信息

• THYROID RECEPTOR LIGANDS
  申请人：KARO BIO AB

  公开号：EP1144370A2

  公开（公告）日：2001-10-17
• US6989402B1
  申请人：——

  公开号：US6989402B1

  公开（公告）日：2006-01-24
• US7288571B2
  申请人：——

  公开号：US7288571B2

  公开（公告）日：2007-10-30
• [EN] NOVEL THYROID RECEPTOR LIGANDS AND METHOD II<br/>[FR] NOUVEAUX LIGANDS DE RECEPTEURS THYROIDIENS ET PROCEDE II
  申请人：KAROBIO AB

  公开号：WO2000039077A2

  公开（公告）日：2000-07-06

  New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, at least one of R2 and R3 being other than hydrogen; R4 is a carboxylic acid amide (CONR'R'') or an acylsulphonamide (CONHSO2R') derivative, or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof; or when n is equal to or greater than one, R4 may be a heteroaromatic moiety which may be substituted or unsubstituted, or an amine (NR'R''). R5 is hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (wherein R5=H). In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T3 regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.
• [EN] THYROMIMETRIC COMPOUNDS IN TREATMENT OF DISEASE RELATED TO SONIC HEDGEHOG SIGNALLING<br/>[FR] COMPOSÉS THYROMIMÉTIQUES UTILISÉS DANS LE TRAITEMENT D'UNE MALADIE ASSOCIÉE À LA VOIE DE SIGNALISATION SONIC HEDGEHOG
  申请人：KAROBIO AB

  公开号：WO2009080835A1

  公开（公告）日：2009-07-02

  This invention relates to compounds for the treatment of disease induced, caused or dependent on activation of the Sonic hedgehog pathway, wherein the compound is a thyromimetic lacking inner-ring iodines. Preferably the compound is of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, formula (I), wherein G is a group selected from: formula (II) (III) (IV) (IV) and the remaining groups/substituents are as defined herein.